Table 2.
Overview of GC-MS methods used for analysis of SCFAs.
| Matrix | Pretreatment | Stationary phase | Detection | LOD | LOQ | Reference |
|---|---|---|---|---|---|---|
| Feces/serum | Derivatization BSTFA | HB-5MS capillary column (30 m × 0.25 mm × 0.25 µm) | MS | 0.064 – 0.067 μM | 1.60 – 1.67 μM | (47) |
| Serum | Protein precipitation | Nukol (30 m × 0.25 mm× 0.25 µm) | MS | 0,12 µM | – | (119) |
| Serum | LLE | DB-FFAP (Free Fatty Acid Phase) column (50 m × 0.32 mm, 0.5 μm) | MS | 0.12 – 0.48 mg.L-1 | 0.40 – 1.61 mg.L-1 | (100) |
| Faeces | LLE | Nukol (30 m × 0.25 mm× 0.25 µm) | MS | 1.6 – 11.3 µg.mL-1 | — | (159) |
| Plasma | Derivatization | DB-5MS capillary column (30 m × 0.25 mm × 0.25 μm) |
MS | 0.07 – 8.09 ng.mL-1 | 25 – 250 ng.mL-1 | (101) |
| Faeces | Derivatization | HP-5 ms (5%-Phenyl-methylpolysiloxane) capillary column (30 m x 0.25 mm x 0.25 μm) | MS | 0.002 – 0.01 µg.mL-1 | 0.02 – 0.09 µg.mL-1 | (153) |
| Acidification, extraction | Nukol (30 m × 0.25 mm× 0.25 µm) | MS | 0.2 – 0.8 µg.mL-1 | 1 – 5 µg.mL-1 | ||
| Faeces/serum | LLE | Stabilwax®-DA (30 m × 0.25 mm × 0.25 μm) | MS | — | 0.03 – 0.08 μM (serum) 4 – 50 μM (faecal water) |
(160) |
| Faeces | Derivatization | DB-5ms DuraGuard (30 m × 0.25 mm × 0.25 μm) | MS | — | — | (161) |
| Serum | LLE | DB-FFAP column (30 m x 0.25 mm x 0.25 μm) | MS | 0.1 – 0.6 µg.mL-1 | — | (162) |
| Faeces | SPME | Supelcowax 10 capillary column (60 m x 0.32 mm) | MS | — | — | (84) |
| Plasma | LLE | DB-FFAP column (30 m x 0.25 mm x 0.25 µm) | MS | 0.01 – 7.58 mg.L-1 | 0.03 – 22.75 mg.L-1 | (163) |
| Faeces | Derivatization | 1st dimension: DB-225 ms (30 m × 0.25 mm × 0.25 μm) 2nd dimension: DB-5 ms (30 m × 0.25 mm × 0.25 μm) |
MS | — | — | (164) |
—, not determined.